Circularly permuted TRAIL - Beijing Sunbio Biotech

Drug Profile

Circularly permuted TRAIL - Beijing Sunbio Biotech

Alternative Names: CPT - Beijing Sunbio Biotech; Human recombinant Apo2L/TRAIL; Human recombinant circularly permuted TRAIL - Beijing Sunbio Biotech; Human recombinant CPT - Beijing Sunbio Biotech; Recombinant Apo2L - Beijing Sunbio Biotech; Recombinant TRAIL

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beijing Sunbio Biotech
  • Developer Beijing Chao-Yang Hospital; Beijing Sunbio Biotech; Fudan University Shanghai Cancer Center
  • Class Antineoplastics; Recombinant proteins
  • Mechanism of Action Apoptosis stimulants; TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma; Solid tumours

Most Recent Events

  • 07 Sep 2017 Discontinued - Phase-II for Multiple myeloma (Combination therapy, Second-line therapy or greater) in China (IV)
  • 07 Sep 2017 Discontinued - Phase-II for Multiple myeloma (Second-line therapy or greater) in China (IV)
  • 07 Sep 2017 Discontinued - Phase-II for Solid tumours (Second-line therapy or greater) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top